http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2009105355-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5033162486b25b032218cece3ffeffa4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_03b81f9c328f9bc2af14034fd2c62f77 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cea139ad438b9ce7d33159d45b154c6b http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a8370afa5b05126abffc93df0ab8ef58 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-552 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-545 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55566 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55561 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P33-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-002 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-002 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P33-02 |
| filingDate | 2009-02-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ce44fa54d76f99f3a64fcf687e93285e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b96e4c72203dbb85f901c554c14431ab http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_aee51b8cfefd941783701efe7e7efb1b |
| publicationDate | 2009-08-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2009105355-A2 |
| titleOfInvention | A novel neospora caninum vaccine |
| abstract | Neospora caninum is the causal agent of bovine neosporosis which results in high levels of abortion. The present study determined the protective efficacy of two Neospora antigens- Neospora cyclophilin (NcCyP) and NcSRS2. The ability of native NcCyP to upregulate mouse IFNγ was also confirmed in this study. Recombinant NcCyP or NcSRS2 were tested either alone or in combination and formulated with adjuvant ImmuMax-SR and CpG. Female BALB/c mice (n=15) of 10-12 weeks of age were immunized s.c. twice in a 2-week interval with vaccines containing either NcCyP alone, NcSRS2 alone, NcCyP plus NcSRS2, or non-recombinant bacterial antigen (NR) in 2 separate trials. All mice were challenge-infected 3 weeks following the booster immunization and necropsied 3 weeks after the challenge infection. Brain and serum were collected and Nc-specific DNA sequence in brain tissue and antibodies in serum were analyzed by PCR or ELISA/Westem blotting. Results showed that mice vaccinated with rNcCyP, rNcSRS2, or both rNcCyP and rNcSRS2 responded with high levels of NcCyP or NcSRS2 specific antibodies. Overall, mice received vaccines formulated with either rNcCyP or rNcCyP and rNcSRS2 had a higher (p<0.01) percent protection when compared to the mock- or non-vaccinated mice. The groups immunized with rNcSRS2 alone exhibited slightly lower levels of protection, which was higher (p<0.05) than that of the non-vaccinated group but did not differ (p=0.06) from that of the mock-vaccinated group. The results of the present study indicate that NcCyP is a highly efficacious vaccine candidate which may be useful in protection against Neospora infection. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-104312922-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102455360-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2019182751-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112279925-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2388416-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112279925-B |
| priorityDate | 2008-02-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 503.